Latest Endologix Inc (ELGX) Headlines
Endologix to Participate in Two Investor Conferences in March
GlobeNewswire - Fri Mar 07, 2:59AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first conference is the 26th Annual ROTH Conference in Dana Point, CA.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Endologix Inc. Shares Were Clobbered
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:53PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endologix , a developer of medical devices...
Will This Downgrade Hurt Endologix (ELGX) Today?
at The Street - Fri Feb 28, 8:45AM CST
Oppenheimer downgraded Endologix (ELGX) to "perform" from "outperform" and set a $16 target price. The firm noted domestic business is facing increased competition.
Downgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Fri Feb 28, 7:06AM CST
Endologix (NASDAQ:ELGX) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $17.87 on volume of 596,000 shares, above average daily volume of 398,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
Endologix Reports 25% and 21% Revenue Growth for the Full Year and Fourth Quarter 2013
GlobeNewswire - Thu Feb 27, 3:14PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2013.
Endologix Announces US Launch of the VELA(TM) Proximal Endograft System
GlobeNewswire - Mon Feb 10, 8:39AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the United States launch of its new VELA(TM) Proximal Endograft System. The VELA Proximal Endograft is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair ('EVAR') procedure using the Endologix AFX Endovascular AAA System. The proximal neck is the portion of the aorta that is above the aneurysm and below the renal arteries.
Endologix to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
GlobeNewswire - Thu Feb 06, 3:15PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2013 financial results, which will take place on Thursday, February 27, 2014 after the close of the market.
Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial
GlobeNewswire - Tue Jan 21, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS FORWARD-IDE clinical trial, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System") for the endovascular repair of infrarenal abdominal aortic aneurysms. The EVAS FORWARD-IDE clinical trial is approved to enroll 180 patients at up to 30 centers in the U.S., Canada and Europe, of which approximately 25 will be in the U.S. The first procedure was performed by Professor Dittmar Boeckler, MD, a vascular surgeon at Heidelberg University Hospital in Germany.
Healthcare Conference Schedules and Additional Loans - Research Report on Clovis Oncology, LifePoint, Halozyme, Infinity, and Endologix
PR Newswire - Thu Jan 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Clovis Oncology, Inc. (NASDAQ: CLVS), LifePoint Hospitals, Inc. (NASDAQ: LPNT), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Endologix, Inc. (NASDAQ: ELGX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 32 Annual JP Morgan Healthcare Conference in San Francisco, CA.
Acquisitions, Appointments, FDA Approvals, and Study Milestones - Research Report on Jazz Pharmaceuticals, Boston Scientific, NuVasive, Endologix, and bluebird bio
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), Boston Scientific Corporation (NYSE: BSX), NuVasive, Inc. (NASDAQ: NUVA), Endologix Inc. (NASDAQ: ELGX), and bluebird bio, Inc. (NASDAQ: BLUE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix Receives IDE Approval for the Nellix(R) EndoVascular Aneurysm Sealing System
GlobeNewswire - Fri Dec 20, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to begin a pivotal clinical trial to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("EVAS") for the endovascular repair of infrarenal abdominal aortic aneurysms. The study, EVAS FORWARD-IDE, is one of a number of clinical studies that make up the broader EVAS FORWARD Clinical Program aimed at establishing clinical and economic evidence for EVAS using Nellix. The EVAS FORWARD-IDE study is approved to enroll 180 patients at up to 30 sites in the U.S., Canada and Europe.
Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
PR Newswire - Fri Dec 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Hologic Inc. (NASDAQ: HOLX), IDEXX Laboratories, Inc. (NASDAQ: IDXX), Endologix Inc. (NASDAQ: ELGX) and Healthways Inc. (NASDAQ: HWAY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix Announces Pricing of $75 Million of Convertible Notes
GlobeNewswire - Thu Dec 05, 7:30AM CST
Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced the pricing of its public offering of $75 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes") in an offering registered under the Securities Act of 1933, as amended. The Company granted an option to the underwriters for up to an additional $11.25 million aggregate principal amount of Convertible Notes solely to cover overallotments. The Convertible Notes will pay interest semiannually at a rate of 2.25% and will be convertible into shares of the Company's common stock ("Common Stock"), cash or a combination of cash and shares of the Company's Common Stock, at the Company's election, based on the applicable conversion rate at such time. The Convertible Notes have an initial conversion rate of 41.6051 shares of the Company's Common Stock per $1,000 principal amount of the Convertible Notes (which is equal to an initial conversion price of approximately $24.04 per share of the Company's Common Stock), representing an initial conversion premium of approximately 32.5% above the closing price of $18.14 per share of the Company's Common Stock on December 4, 2013. The Convertible Notes will mature on December 15, 2018, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to September 15, 2018, the Convertible Notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. On or after December 15, 2016, the Company may from time to time redeem for cash all or part of the Convertible Notes in certain circumstances. The Company expects to close the sale of the Convertible Notes on or about December 10, 2013, subject to the satisfaction of various customary closing conditions.
Marketing Approval, Presentation Schedules, Supplier Agreement, and Management Changes - Research Report on ImmunoGen, Endologix, Unilife, Sangamo, and Dynavax
PR Newswire - Thu Dec 05, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Endologix Has Returned 29.8% Since SmarTrend Recommendation (ELGX)
Comtex SmarTrend(R) - Wed Dec 04, 9:15AM CST
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on July 2nd, 2013 at $14.04. In approximately 5 months, Endologix has returned 29.82% as of today's recent price of $18.22.
Endologix Announces Offering of $75 Million of Convertible Notes
GlobeNewswire - Tue Dec 03, 3:01PM CST
Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced that it intends, subject to market and other conditions, to offer $75 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes") in an offering registered under the Securities Act of 1933, as amended. The Company expects to grant an option to the underwriters for up to an additional $11.25 million aggregate principal amount of Convertible Notes solely to cover overallotments. The Convertible Notes are expected to pay interest semiannually and will be convertible into shares of the Company's common stock ("Common Stock"), cash or a combination of cash and shares of the Company's Common Stock, at the Company's election, based on a conversion rate to be determined at the pricing of the Convertible Notes. The Convertible Notes will mature on December 15, 2018, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to September 15, 2018, the Convertible Notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. On or after December 15, 2016, the Company may from time to time redeem for cash all or part of the Convertible Notes in certain circumstances.
Endologix to Participate in Two Investor Conferences in March
GlobeNewswire - Fri Mar 07, 2:59AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first conference is the 26th Annual ROTH Conference in Dana Point, CA.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Endologix Inc. Shares Were Clobbered
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:53PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endologix , a developer of medical devices...
Will This Downgrade Hurt Endologix (ELGX) Today?
at The Street - Fri Feb 28, 8:45AM CST
Oppenheimer downgraded Endologix (ELGX) to "perform" from "outperform" and set a $16 target price. The firm noted domestic business is facing increased competition.
Downgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Fri Feb 28, 7:06AM CST
Endologix (NASDAQ:ELGX) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $17.87 on volume of 596,000 shares, above average daily volume of 398,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
Endologix Reports 25% and 21% Revenue Growth for the Full Year and Fourth Quarter 2013
GlobeNewswire - Thu Feb 27, 3:14PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2013.
Endologix Announces US Launch of the VELA(TM) Proximal Endograft System
GlobeNewswire - Mon Feb 10, 8:39AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the United States launch of its new VELA(TM) Proximal Endograft System. The VELA Proximal Endograft is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair ('EVAR') procedure using the Endologix AFX Endovascular AAA System. The proximal neck is the portion of the aorta that is above the aneurysm and below the renal arteries.
Endologix to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
GlobeNewswire - Thu Feb 06, 3:15PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2013 financial results, which will take place on Thursday, February 27, 2014 after the close of the market.
Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial
GlobeNewswire - Tue Jan 21, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS FORWARD-IDE clinical trial, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System") for the endovascular repair of infrarenal abdominal aortic aneurysms. The EVAS FORWARD-IDE clinical trial is approved to enroll 180 patients at up to 30 centers in the U.S., Canada and Europe, of which approximately 25 will be in the U.S. The first procedure was performed by Professor Dittmar Boeckler, MD, a vascular surgeon at Heidelberg University Hospital in Germany.
Healthcare Conference Schedules and Additional Loans - Research Report on Clovis Oncology, LifePoint, Halozyme, Infinity, and Endologix
PR Newswire - Thu Jan 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Clovis Oncology, Inc. (NASDAQ: CLVS), LifePoint Hospitals, Inc. (NASDAQ: LPNT), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Endologix, Inc. (NASDAQ: ELGX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 32 Annual JP Morgan Healthcare Conference in San Francisco, CA.
Acquisitions, Appointments, FDA Approvals, and Study Milestones - Research Report on Jazz Pharmaceuticals, Boston Scientific, NuVasive, Endologix, and bluebird bio
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), Boston Scientific Corporation (NYSE: BSX), NuVasive, Inc. (NASDAQ: NUVA), Endologix Inc. (NASDAQ: ELGX), and bluebird bio, Inc. (NASDAQ: BLUE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix Receives IDE Approval for the Nellix(R) EndoVascular Aneurysm Sealing System
GlobeNewswire - Fri Dec 20, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to begin a pivotal clinical trial to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("EVAS") for the endovascular repair of infrarenal abdominal aortic aneurysms. The study, EVAS FORWARD-IDE, is one of a number of clinical studies that make up the broader EVAS FORWARD Clinical Program aimed at establishing clinical and economic evidence for EVAS using Nellix. The EVAS FORWARD-IDE study is approved to enroll 180 patients at up to 30 sites in the U.S., Canada and Europe.
Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
PR Newswire - Fri Dec 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Hologic Inc. (NASDAQ: HOLX), IDEXX Laboratories, Inc. (NASDAQ: IDXX), Endologix Inc. (NASDAQ: ELGX) and Healthways Inc. (NASDAQ: HWAY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix Announces Pricing of $75 Million of Convertible Notes
GlobeNewswire - Thu Dec 05, 7:30AM CST
Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced the pricing of its public offering of $75 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes") in an offering registered under the Securities Act of 1933, as amended. The Company granted an option to the underwriters for up to an additional $11.25 million aggregate principal amount of Convertible Notes solely to cover overallotments. The Convertible Notes will pay interest semiannually at a rate of 2.25% and will be convertible into shares of the Company's common stock ("Common Stock"), cash or a combination of cash and shares of the Company's Common Stock, at the Company's election, based on the applicable conversion rate at such time. The Convertible Notes have an initial conversion rate of 41.6051 shares of the Company's Common Stock per $1,000 principal amount of the Convertible Notes (which is equal to an initial conversion price of approximately $24.04 per share of the Company's Common Stock), representing an initial conversion premium of approximately 32.5% above the closing price of $18.14 per share of the Company's Common Stock on December 4, 2013. The Convertible Notes will mature on December 15, 2018, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to September 15, 2018, the Convertible Notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. On or after December 15, 2016, the Company may from time to time redeem for cash all or part of the Convertible Notes in certain circumstances. The Company expects to close the sale of the Convertible Notes on or about December 10, 2013, subject to the satisfaction of various customary closing conditions.
Marketing Approval, Presentation Schedules, Supplier Agreement, and Management Changes - Research Report on ImmunoGen, Endologix, Unilife, Sangamo, and Dynavax
PR Newswire - Thu Dec 05, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Endologix Has Returned 29.8% Since SmarTrend Recommendation (ELGX)
Comtex SmarTrend(R) - Wed Dec 04, 9:15AM CST
SmarTrend identified an Uptrend for Endologix (NASDAQ:ELGX) on July 2nd, 2013 at $14.04. In approximately 5 months, Endologix has returned 29.82% as of today's recent price of $18.22.
Endologix Announces Offering of $75 Million of Convertible Notes
GlobeNewswire - Tue Dec 03, 3:01PM CST
Endologix, Inc. (Nasdaq:ELGX) ("Endologix" or the "Company") today announced that it intends, subject to market and other conditions, to offer $75 million aggregate principal amount of convertible senior notes due 2018 (the "Convertible Notes") in an offering registered under the Securities Act of 1933, as amended. The Company expects to grant an option to the underwriters for up to an additional $11.25 million aggregate principal amount of Convertible Notes solely to cover overallotments. The Convertible Notes are expected to pay interest semiannually and will be convertible into shares of the Company's common stock ("Common Stock"), cash or a combination of cash and shares of the Company's Common Stock, at the Company's election, based on a conversion rate to be determined at the pricing of the Convertible Notes. The Convertible Notes will mature on December 15, 2018, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to September 15, 2018, the Convertible Notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. On or after December 15, 2016, the Company may from time to time redeem for cash all or part of the Convertible Notes in certain circumstances.
